This webinar will present an overview of the use of ketamine to treat depression.
This presentation will provide an introduction to treatment resistant depression and ketamine as a rapid acting, highly effective treatment. It will also cover an overview of formulations of ketamine and ways of giving the drug and identify current gaps in knowledge. Our speaker will also present results from KADS, a large multisite Australasian randomised control trial of generic ketamine in treatment resistant depression and implications for clinical practice.
About the speaker
Colleen Loo is a psychiatrist, Australian National Health and Medical Research Council Leadership Fellow and Professor of Psychiatry at UNSW Sydney and the Black Dog Institute. She is an internationally recognised clinical expert and researcher in the fields of electroconvulsive therapy, Transcranial Magnetic Stimulation, transcranial Direct Current Stimulation and ketamine, and led the first Australian RCTs of these interventions in depression. She has published over 200 peer reviewed papers and has received competitive grant funding from major Australian and overseas grant funding agencies.
Professor Loo is active in ECT, Neurostimulation and novel treatments research, practice and policy, providing advice to Australian government health departments, the Royal Australian and New Zealand College of Psychiatrists, and several international guidelines. She was President of the International Society for ECT and Neurostimulation (ISEN) 2018-2020. She has served on the Editorial Boards of the two leading international brain stimulation journals: Journal of ECT, Brain Stimulation. She directs professional training courses in ECT, TMS, tDCS and ketamine.